PIII — P3 Health Partners Share Price
0.000.00%
Last trade - 00:00- $1.78bn
- $1.97bn
- $1.50bn
- 21
- 27
- 24
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 23.45 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.19 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -111.73% | ||
| Return on Equity | -124.59% | ||
| Operating Margin | -21.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 485.54 | 637.36 | 1,049.47 | 1,266.38 | 1,500.45 | 1,408.04 | 1,497.61 | 59.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 20th, 2020
- Public Since
- February 10th, 2021
- No. of Shareholders
- 63
- No. of Employees
- 360
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 199,220,175
- Address
- 2045 W Grand Ave Ste B, Pmb # 82152, CHICAGO, 60612-1577
- Web
- https://ir.p3hp.org/
- Phone
- +1 3128228897
- Contact
- Ryan Halstead
- Auditors
- BDO USA, P.C.
Upcoming Events for PIII
P3 Health Partners Inc Annual Shareholders Meeting
P3 Health Partners Inc Annual Shareholders Meeting
Q2 2025 P3 Health Partners Inc Earnings Release
Similar to PIII
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the P3 Health Partners share price?
As of Today at 22:32 UTC, shares in P3 Health Partners are trading at $8.94. This share price information is delayed by 15 minutes.
How has the P3 Health Partners share price performed this year?
Shares in P3 Health Partners last closed at $8.94 and the price had moved by -62.74% over the past 365 days. In terms of relative price strength the P3 Health Partners share price has underperformed the S&P500 Index by -65.61% over the past year.
What are the analyst and broker recommendations for P3 Health Partners?
The overall consensus recommendation for P3 Health Partners is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the P3 Health Partners dividend yield?
P3 Health Partners does not currently pay a dividend.
Does P3 Health Partners pay a dividend?
P3 Health Partners does not currently pay a dividend.
When does P3 Health Partners next pay dividends?
P3 Health Partners does not currently pay a dividend.
How do I buy P3 Health Partners shares?
To buy shares in P3 Health Partners you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of P3 Health Partners?
As of the previous close price of $8.94, shares in P3 Health Partners had a market capitalisation of $1.78bn.
Where are P3 Health Partners shares listed?
Here are the trading details for P3 Health Partners:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PIII
What kind of share is P3 Health Partners?
Based on an overall assessment of its quality, value and momentum P3 Health Partners is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a P3 Health Partners share price forecast for 2025?
The analyst consensus target price for shares in P3 Health Partners is $27.50. That is 207.61% above the last closing price of $8.94.
Analysts covering P3 Health Partners currently have a consensus Earnings Per Share (EPS) forecast of -$24.24 for the next financial year.
Find out moreWhat is the trend in the P3 Health Partners share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like P3 Health Partners. Over the past six months, its share price has underperformed the S&P500 Index by -53.59%.
As of the last closing price of $8.94, shares in P3 Health Partners were trading -44.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the P3 Health Partners PE Ratio?
The P3 Health Partners PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of P3 Health Partners?
We do not have data on P3 Health Partners' directors